Genomics, a 2014 life sciences spin-out from Oxford University, has raised £10.3m ($16.24m) in a series A round.
Oxford University is one of the investors in the round, and is joined by commercialisation investor IP Group, a separate investment from IP Group’s IP Venture Fund II, Invesco Perpetual, Lansdowne Partners, Woodford Investment Management, and the Wylie Family Trust.
The UK-based company is developing a genomic sequence data analysis platform, and is already working with pharmaceutical companies to bring the fruits…
